Dietary carbohydrates play an important role in mood regulation, mental health, and cognitive performance, which is driving rapid development in studies on the diet‐brain interaction. The review will focus on the intricate relationship between brain function and carbohydrate intake, emphasizing how different types of carbohydrates impact mental health and cognitive outcomes. Simple carbohydrate intake (often known as “sugars”) is consistently linked to a decline in overall cognition, while complex carbohydrate intake is linked to both short‐ and long‐term memory improvement and successful brain aging. Dietary macronutrients affect the brain and cognition through a variety of pathways, including glucose and insulin metabolism, neurotransmitter effects, and cerebral oxidation and inflammation. Carbohydrate supplements appear to enhance cognitive function in people who engage in prolonged, high‐intensity physical activity with high energy requirements.

Pandoraea species are emerging multidrug-resistant pathogens increasingly associated with respiratory tract infections, particularly in cystic fibrosis patients. Despite their growing clinical relevance, these bacteria are underrepresented in the scientific literature. This review aims to consolidate existing evidence regarding Pandoraea species as emerging multidrug-resistant pathogens, with a focus on their taxonomy, diagnostic methodologies, antimicrobial resistance mechanisms, and treatment challenges. By identifying gaps in current therapeutic strategies and the limited clinical outcome data, this review underscores the necessity of advancing research into innovative interventions, such as bacteriophages, antimicrobial peptides, and combination therapies, to enhance patient management and infection control. A comprehensive literature search was conducted using PubMed and Google Scholar, employing relevant keywords to identify case reports, clinical studies, and in vitro research related to Pandoraea infections, resistance mechanisms, and therapeutic strategies. Our findings reveal a significant lack of comprehensive data on therapeutic approaches, particularly concerning bacteriophages, antimicrobial peptides, and combination antibiotic therapies. Furthermore, clinical data on treatment efficacy remain sparse, with the majority of evidence stemming from in vitro studies rather than real-world clinical settings. This review emphasizes the urgent need for further research to address these knowledge deficits and to develop effective therapeutic interventions against Pandoraea infections.

Methicillin-resistant Staphylococcus aureus (MRSA) is a major pathogen causing infections ranging from skin disorders to severe conditions like infective endocarditis. Its evolving resistance, including resistance to β-lactams and last-resort antibiotics, such as vancomycin, daptomycin, and linezolid, necessitates alternative therapies. This study investigates the synergistic efficacy of vancomycin and 3-hydrazinoquinoxaline-2-thiol (3HL) against 23 clinical MRSA isolates. Susceptibility testing was performed using broth microdilution and checkerboard assays, while in silico analyses assessed interactions between vancomycin and 3HL. Vancomycin exhibited minimum inhibitory concentrations (MICs) ranging from 0.25 to 1 µg/mL, whereas 3HL showed higher MICs of 16–32 µg/mL. Synergistic interactions were confirmed via checkerboard assays, with fractional inhibitory concentration index (FICI) values between 0.236 and 0.5, indicating enhanced vancomycin efficacy. Notably, vancomycin MICs decreased significantly when combined with 3HL. In silico docking revealed interactions with penicillin-binding protein 2a (PBP2a), suggesting promising therapeutic potential. Vancomycin exhibited superior docking scores (−8.9 kcal/mol) and stabilizing hydrogen bonds, effectively targeting key protein grooves. Both compounds demonstrated potential for overcoming PBP2a’s structural occlusions, suggesting their role in combating β-lactam-resistant strains through targeted protein inhibition and structural stabilization.

This study presents a novel multifunctional Lac@CMC-Cu@Fe₃O₄ nanocomposite for the efficient immobilization of laccase designed to overcome limitations in enzyme stability, reusability, and catalytic performance. The nanocomposite integrates magnetite (Fe₃O₄) for rapid magnetic separation, carboxymethyl cellulose (CMC) as a biocompatible matrix for covalent enzyme attachment, and copper nanoparticles to enhance catalytic activity. The immobilization achieved an impressive yield of 87%, with comprehensive characterization by XRD, FT-IR, FESEM, EDX, BET, and VSM confirming successful synthesis and enzyme attachment. Kinetic analysis revealed a remarkable 37% increase in maximum reaction velocity (Vmax = 111 µmol/min) compared to free laccase (81.3 µmol/min), despite a moderate increase in Km from 1.54 to 3.22 mM. The immobilized biocatalyst demonstrated superior thermal stability, retaining 53% activity at 60 °C versus 17% for the free enzyme, and exhibited a broader pH tolerance, maintaining 41% activity at pH 8.0. Notably, the biocatalyst showed enhanced performance in organic solvents, with 153% activation in acetone. Operational reusability was exceptional, retaining 84% activity after 15 cycles, and storage stability was significantly improved, maintaining 68% activity after 90 days compared to only 11% for free laccase. This magnetically separable nanobiocatalyst represents a promising, scalable platform for sustainable industrial and environmental applications.

Background: A member of the quinoxaline family, 2,3-dimethylquinoxaline (DMQ), has been evaluated for associated nephroprotective properties in an in vivo model system to assess renal inflammation induced by the anticancer drug doxorubicin (DOX). Methods: Rats were administered DMQ at doses of 30 or 60 mg/kg body weight once daily for 7 consecutive days. Additionally, a single intraperitoneal (i.p.) dose of DOX (15 mg/kg body weight) was administered on the sixth day. DMQ-mediated nephroprotective effects were assessed by measuring renal function markers, oxidative stress markers, lipid peroxidation, renal stress markers, proinflammatory cytokines, and inflammatory mediator levels, as well as by performing histopathological examination of kidney tissues. Results: DMQ-treated rats exhibited a marked reduction in kidney toxicity markers and restoration of antioxidant enzyme levels, leading to attenuated oxidative stress. DMQ administration also reduced proinflammatory cytokines, renal stress markers, and inflammatory mediators. Furthermore, DMQ may also attenuate DOX-induced renal structural damage and help restore the dilated capsular space and other histopathological alterations in kidney tissues. Conclusion: These findings suggest that DMQ may protect against DOX-induced renal damage by alleviating oxidative stress and inflammation in a rat model, indicating the potential of DMQ as a nephroprotective agent.